Tekla Life Sciences Stock Working Capital

HQL Stock  USD 14.26  0.13  0.92%   
Tekla Life Sciences fundamentals help investors to digest information that contributes to Tekla Life's financial success or failures. It also enables traders to predict the movement of Tekla Stock. The fundamental analysis module provides a way to measure Tekla Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tekla Life stock.
Last ReportedProjected for Next Year
Change In Working Capital-60.4 M-57.4 M
Change In Working Capital is expected to rise to about (57.4 M) this year.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Tekla Life Sciences Company Working Capital Analysis

Tekla Life's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

 = 

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Tekla Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Tekla Life is extremely important. It helps to project a fair market value of Tekla Stock properly, considering its historical fundamentals such as Working Capital. Since Tekla Life's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tekla Life's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tekla Life's interrelated accounts and indicators.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition

Tekla Capital Stock

Capital Stock

229,065

At this time, Tekla Life's Capital Stock is quite stable compared to the past year.
According to the company's disclosures, Tekla Life Sciences has a Working Capital of 0.0. This is 100.0% lower than that of the Capital Markets sector and 100.0% lower than that of the Financials industry. The working capital for all United States stocks is 100.0% higher than that of the company.

Did you try this?

Run Portfolio Center Now

   

Portfolio Center

All portfolio management and optimization tools to improve performance of your portfolios
All  Next Launch Module

Tekla Life ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tekla Life's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tekla Life's managers, analysts, and investors.
Environment Score
Governance Score
Social Score

Tekla Fundamentals

About Tekla Life Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Tekla Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tekla Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tekla Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Tekla Life Sciences is a strong investment it is important to analyze Tekla Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tekla Life's future performance. For an informed investment choice regarding Tekla Stock, refer to the following important reports:
Check out Tekla Life Piotroski F Score and Tekla Life Altman Z Score analysis.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.425
Dividend Share
1.3
Earnings Share
1.34
Revenue Per Share
0.134
Quarterly Revenue Growth
0.07
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.